Avacta Group Crecimiento futuro

Future controles de criterios 1/6

Se prevé que los beneficios de Avacta Group disminuyan en un 3.5% al año, mientras que se espera que sus ingresos anuales crezcan en un 8.8% al año. Se prevé que el BPA crezca en un 7.1% por año. Se espera que la rentabilidad financiera sea de -63% en 3 años.

Información clave

-3.5%

Tasa de crecimiento de los beneficios

7.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	26.8%
Tasa de crecimiento de los ingresos	10.8%
Rentabilidad financiera futura	-63.0%
Cobertura de analistas	Low
Última actualización	20 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet

Jun 21

This Is The Reason Why We Think Avacta Group Plc's (LON:AVCT) CEO Deserves A Bump Up To Their Compensation

Jun 22

Avacta Group (LON:AVCT) Is In A Good Position To Deliver On Growth Plans

Jun 20

Avacta Group Plc (LON:AVCT) Insiders Have Been Selling

Feb 18

Companies Like Avacta Group (LON:AVCT) Are In A Position To Invest In Growth

Jan 23

What Kind Of Shareholders Hold The Majority In Avacta Group Plc's (LON:AVCT) Shares?

Dec 27

How Is Avacta Group's (LON:AVCT) CEO Paid Relative To Peers?

Dec 06

Previsiones de crecimiento de beneficios e ingresos

AIM:AVCT - Estimaciones futuras de los analistas y datos financieros pasados (GBP Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	32	-25	N/A	N/A	1
12/31/2025	29	-34	-28	-24	3
12/31/2024	24	-35	-33	-24	2
12/31/2023	23	-25	-16	-15	N/A
9/30/2023	20	-32	-16	-15	N/A
6/30/2023	16	-42	-16	-15	N/A
3/31/2023	13	-41	-16	-16	N/A
12/31/2022	10	-37	-17	-16	N/A
9/30/2022	8	-31	-19	-18	N/A
6/30/2022	7	-25	-21	-20	N/A
3/31/2022	5	-26	-21	-20	N/A
12/31/2021	3	-26	-22	-21	N/A
6/30/2021	2	-20	-18	-16	N/A
3/31/2021	2	-18	-15	-14	N/A
12/31/2020	2	-16	-12	-11	N/A
6/30/2020	5	-12	-9	-8	N/A
3/31/2020	4	-12	-10	-9	N/A
12/31/2019	4	-11	-11	-9	N/A
7/31/2019	4	-10	-10	-8	N/A
4/30/2019	3	-10	-9	-6	N/A
1/31/2019	2	-10	-7	-5	N/A
10/31/2018	3	-9	-8	-5	N/A
7/31/2018	3	-9	-8	-5	N/A
4/30/2018	3	-8	-8	-6	N/A
1/31/2018	3	-7	-8	-6	N/A
10/31/2017	3	-7	N/A	-5	N/A
7/31/2017	3	-6	N/A	-4	N/A
4/30/2017	3	-6	N/A	-4	N/A
1/31/2017	2	-6	N/A	-5	N/A
10/31/2016	2	-5	N/A	-4	N/A
7/31/2016	2	-5	N/A	-4	N/A
4/30/2016	2	-5	N/A	-3	N/A
1/31/2016	2	-5	N/A	-3	N/A
10/31/2015	2	-5	N/A	-3	N/A
7/31/2015	2	-5	N/A	-3	N/A
4/30/2015	2	-4	N/A	-2	N/A
1/31/2015	2	-3	N/A	-2	N/A
10/31/2014	2	-2	N/A	-1	N/A
7/31/2014	2	-1	N/A	-1	N/A
4/30/2014	2	-1	N/A	-1	N/A
1/31/2014	2	-1	N/A	-1	N/A
10/31/2013	3	-1	N/A	-1	N/A
7/31/2013	3	-2	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que AVCT siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que AVCT siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que AVCT siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (8.8% al año) de AVCT crezcan más rápidamente que los del mercado UK (3.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 8.8% al año) de AVCT crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: AVCT se prevé que no sea rentable en 3 años.

Avacta Group Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 13% to UK£1.38

Price target decreased to UK£1.55

Price target decreased to UK£1.55

Price target decreased to UK£2.55

Analysts lower revenue estimates to UK£3.90m

Recent updates

Improved Revenues Required Before Avacta Group Plc (LON:AVCT) Shares Find Their Feet

Avacta Group plc Announces Board Changes

Avacta Group Plc, Annual General Meeting, Jun 26, 2024

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Full year 2023 earnings: EPS misses analyst expectations

New minor risk - Financial data availability

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Investors Give Avacta Group Plc (LON:AVCT) Shares A 26% Hiding

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Price target decreased by 13% to UK£1.38

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

First half 2023 earnings released: UK£0.043 loss per share (vs UK£0.036 loss in 1H 2022)

New major risk - Financial position

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

New minor risk - Share price stability

Getting In Cheap On Avacta Group Plc (LON:AVCT) Is Unlikely

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Would Avacta Group (LON:AVCT) Be Better Off With Less Debt?

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Price target decreased to UK£1.55

High number of new and inexperienced directors

Price target decreased to UK£1.55

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

First half 2022 earnings released: UK£0.036 loss per share (vs UK£0.041 loss in 1H 2021)

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

High number of new and inexperienced directors

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Less than half of directors are independent

Full year 2021 earnings released: UK£0.11 loss per share (vs UK£0.084 loss in FY 2020)

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development

Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU

Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000

We're Hopeful That Avacta Group (LON:AVCT) Will Use Its Cash Wisely

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.037 loss in 1H 2020)

Avacta Group Plc Announces Pre-Clinical Development Milestone in LG Chem Life Sciences Partnership

Price target decreased to UK£2.55

Avacta Group plc Provides Update on AffiDX Lateral Flow Test

This Is The Reason Why We Think Avacta Group Plc's (LON:AVCT) CEO Deserves A Bump Up To Their Compensation

Avacta Group (LON:AVCT) Is In A Good Position To Deliver On Growth Plans

Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU

MHRA Confirms Registration of Avacta’s Affidx® SARS-CoV-2 Antigen Lateral Flow Test

Avacta Group plc Provides an Update on Lateral Flow Test Regulatory Submissions

Full year 2020 earnings released: UK£0.084 loss per share (vs UK£0.092 loss in FY 2019)

Full year 2020 earnings released: UK£0.084 loss per share (vs UK£0.092 loss in FY 2019)

Avacta Signs Diagnostic Licensing Deal with Biokit

Avacta Group plc Announces its AffiDX SARS-CoV-2 Rapid Antigen Lateral Flow Test Detects the Dominant New Variants of the Coronavirus

Avacta Announces Phase 1 Clinical Trial Authorisation (CTA) for AVA6000 Approved by MHRA

Avacta Group Plc (LON:AVCT) Insiders Have Been Selling